Cyteir Therapeutics Inc

$2.48 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Cyteir Therapeutics Inc

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing precision oncology medicines that inhibit deoxyribonucleic acid (DNA) damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. The Company's pipeline includes CYT-0851 and CYT-1853. Its lead program, CYT-0851, is an oral, once-daily, small molecule inhibitor of RAD51-mediated homologous recombination (HR), a DNA repair pathway critical for the survival of some cancers. The Company is developing CYT-1853 as an inhibitor of RAD51-mediated HR.

Stock Analysis

last close $2.48
1-mo return -33.9%
3-mo return 45.9%
avg daily vol. 65.34T
52-week high 21.69
52-week low 1.56
market cap. $88M
forward pe -
annual div. -
roe -27.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 79.3%
baraka

Subscribe now for daily local and international financial news

Subscribe